CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of lung cancer.
  
  LEARNING OBJECTIVES

  • Review recent therapeutic advances related to the use of anti-PD-1/PD-L1 antibodies as monotherapy or in combination with chemotherapy, chemobiologic therapy or other immunotherapy for metastatic non-small cell lung cancer (NSCLC), and consider the clinical and biologic factors affecting the recommendation of one approach versus the others.
  • Review available Phase III research data documenting the efficacy and safety of durvalumab in combination with tremelimumab and chemotherapy as first-line treatment for NSCLC, in preparation for the potential availability of this novel regimen.
  • Evaluate the current scientific understanding of mechanisms of primary and acquired resistance to immune checkpoint inhibition in patients with NSCLC, and consider the implications for biomarker assessment and disease management.
  • Recall ongoing clinical trials and emerging data with promising novel agents and strategies in clinical development for patients with primary or acquired resistance to immune checkpoint inhibition.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  John V Heymach, MD, PhD
  Professor and Chair
  Thoracic/Head and Neck Medical Oncology
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, BrightPath Biotherapeutics Co Ltd, Bristol-Myers Squibb Company, Catalyst Pharmaceuticals, Chugai Pharmaceutical Co Ltd, EMD Serono Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Hengrui Therapeutics Inc, Janssen Biotech Inc, Lilly, Mirati Therapeutics Inc, Nexus Health Systems, Pneuma Respiratory, RefleXion, Sanofi, Spectrum Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Research Support: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Spectrum Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Royalties and Licensing Fees: Spectrum Pharmaceuticals Inc.
  
  Stephen V Liu, MD
  Associate Professor of Medicine
  Georgetown University Hospital
  Washington, DC
  
  Advisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Bristol-Myers Squibb Company, Catalyst Pharmaceuticals, Eisai Inc, Elevation Oncology, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Novartis, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Catalyst Pharmaceuticals, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Merck Sharp & Dohme LLC, Novartis, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc, Turning Point Therapeutics Inc; Contracted Research: Alkermes, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Bristol-Myers Squibb Company, Elevation Oncology, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, Merus BV, Nuvalent, Pfizer Inc, Rain Therapeutics, RAPT Therapeutics, Turning Point Therapeutics Inc; Data and Safety Monitoring Board/Committee: Candel.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
  
  This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.
  
  Release date: November 2022
  Expiration date: November 2023